You are here

  • Home
  • Archive
  • Volume 92, Issue 1
  • Aqueous humor levels of asymmetric dimethylarginine (ADMA) are positively associated with monocyte chemoattractant protein-1 (MCP-1) in patients with uveitis

Article Text

Article menu
Download PDFPDF
Original Article
Aqueous humor levels of asymmetric dimethylarginine (ADMA) are positively associated with monocyte chemoattractant protein-1 (MCP-1) in patients with uveitis
  1. Y Yoshida1,
  2. S Yamagishi2,
  3. S Ueda2,
  4. K Yoshimura1,
  5. S Okuda2,
  6. R Yamakawa1
  1. 1
    Department of Ophthalmology, Kurume University School of Medicine, Kurume 830-0011, Japan
  2. 2
    Departments of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan
  1. S Yamagishi, Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume, 830-0011, Japan; shoichi{at}med.kurume-u.ac.jp

Abstract

Background/aims: The aim of the study was to evaluate whether aqueous humor levels of asymmetric dimethylarginine (ADMA) are associated with monocyte chemoattractant protein-1 (MCP-1).

Methods: Aqueous humor levels of ADMA and MCP-1 were measured by high-performance liquid chromatography (HPLC) and ELISA, respectively, in 31 uveitis samples and nine cataract control samples.

Results: Aqueous humor ADMA and MCP-1 levels were significantly higher in infectious or non-infectious uveitis patients than in controls (0.67±0.04 nmol/ml vs 0.55±0.03 nmol/ml vs 0.43±0. 04 nmol/ml (p<0.01) and 29.0±11.3 ng/ml vs 4.5±1.2 ng/ml vs 0.47±0.1 ng/ml (p<0.01), respectively). A positive correlation between ADMA and MCP-1 levels in aqueous humor was found in control and uveitis patients (r = 0.33, p<0.05).

Conclusion: The results demonstrated that aqueous humor levels of ADMA were positively associated with MCP-1 in humans. Our present observations suggest that aqueous humor levels of ADMA may be a novel biomarker of inflammation in uveitis.

https://doi.org/10.1136/bjo.2007.124966

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Competing interests: None